⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Cognivue Clarity® in the Detection of Biomarker Confirmed Mild Cognitive Impairment and Alzheimer’s Disease (P5-9.008)

James E. Galvin Michael J. Kleiman Heather M. Harris Paul W. Estes

View Full Paper

Ask AI

Bookmark

Share

Abstract

Demonstrate the utility of Cognivue Clarity as a digital biomarker of mild cognitive impairment (MCI) and Alzheimer's disease (AD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Galvin et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db643587678024 https://doi.org/10.1212/wnl.0000000000204688

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cognivue Clarity ® Characterizes Mild Cognitive Impairment and Alzheimer’s Disease in Biomarker Confirmed Cohorts in the Bio-Hermes Study2024
2Cognitive Assessment with Cognivue Clarity®: Psychometric Properties and Normative Ranges in a Diverse Population2024 · 7 citations
3COGNITIVE ASSESSMENT WITH COGNIVUE<i>CLARITY</i><sup>®</sup>: PSYCHOMETRIC PROPERTIES AND ENHANCED NORMATIVE RANGES IN A DIVERSE POPULATION2024
4Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivityReview · 2026
5On the Clinimetrics of the Montreal Cognitive Assessment: Cutoff Analysis in Patients with Mild Cognitive Impairment due to Alzheimer’s Disease2024 · 14 citations